Related Experiment Video

Updated: Apr 8, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System

Linjing Shu, Renhuan Huang, Songtao Wu

  • 1State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, No. 14., 3rd Sec., Ren Min Nan Road, Chengdu 610041, P. R. China. xcai@scu.edu.cn.

Current Stem Cell Research & Therapy
|July 1, 2015
PubMed

Insights

Peroxisome proliferator-activated receptor γ (PPARγ) ligands show promise in suppressing digestive system tumors. This review explores their potential as anticancer agents for PPARγ-expressing cancers.

Area of Science:

  • Molecular biology
  • Oncology
  • Gastroenterology

Background:

  • Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor superfamily member.
  • PPARγ is expressed in various cell lines, notably within the digestive system.
  • Ligand activation of PPARγ influences cellular processes relevant to cancer.

Purpose of the Study:

  • To review the role of PPARγ ligands in combating digestive system tumors.
  • To highlight advances in understanding PPARγ's therapeutic potential in these cancers.
  • To explore PPARγ ligands as prospective anticancer agents.

Main Methods:

  • Literature review focusing on PPARγ and digestive system cancers.
  • Analysis of studies investigating PPARγ ligand effects on tumor cell growth.
  • Synthesis of current research on PPARγ-mediated anticancer mechanisms.

Main Results:

  • PPARγ activation suppresses the growth of oral, esophageal, gastric, colorectal, liver, biliary, and pancreatic tumor cells.
  • Evidence suggests PPARγ ligands possess anticancer properties.
  • The therapeutic potential is linked to PPARγ expression in tumor cells.

Conclusions:

  • PPARγ ligands are potential anticancer agents for digestive system tumors expressing PPARγ.
  • Further research into PPARγ-targeted therapies is warranted.
  • Understanding PPARγ's role is crucial for developing new cancer treatments.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
765
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K